Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Oct;64(4):476-81.
doi: 10.1111/j.1365-2125.2007.02907.x. Epub 2007 Apr 18.

Switching statins in Norway after new reimbursement policy: a nationwide prescription study

Solveig Sakshaug  1 , Kari Furu, Øystein Karlstad, Marit Rønning, Svetlana Skurtveit
Affiliations

Switching statins in Norway after new reimbursement policy: a nationwide prescription study

Solveig Sakshaug et al. Br J Clin Pharmacol. 2007 Oct.

Abstract

Aims: To assess the changes in prescribing of statins in Norway after implementation of the new reimbursement regulations for statins in June 2005.

Methods: Data were retrieved from the Norwegian Prescription Database covering the total population in Norway (4.6 million). Outcome measures were the proportion of atorvastatin users switching to simvastatin and changes in the proportion of new statin users receiving simvastatin. Based on retail costs for all statin prescriptions dispensed in Norway, expenditure was measured in Norwegian currency.

Results: One-year prevalences of statin use increased from 6.3 to 6.8% for women and from 7.5 to 8.1% for men from the year before to the year after the new statin regulations. Of atorvastatin users (N = 131,222), 39% switched to simvastatin during the 13-month period after the implementation. The proportion of switching was higher in women (41%) than in men (36%). In May 2005, 48% of the new statin users received simvastatin. The proportion of new users receiving simvastatin increased rapidly after implementation of the new regulations to 68% in June 2005 and reached 92% in June 2006. Expenditure was reduced from 120 million to 95 million Euro when comparing the year before with the year after the new statin regulations.

Conclusions: The new reimbursement policy for statins has had a great impact on physicians' prescribing of statins in Norway. Physicians in Norway acknowledge the importance of contributing to cost containment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proportion (%) of atorvastatin users who switched to simvastatin in the period June 2005 to June 2006, related to dose (tablet strength) of atorvastatin. Norwegian Prescription Database. Women (formula image); men (formula image)
Figure 2
Figure 2
Monthly number of new statin users in Norway from January 2005 to June 2006. Norwegian Prescription Database. Other statins (□); Atorvastatin (formula image); Simvastatin (formula image)
See this image and copyright information in PMC

References

    1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–9. - PubMed
    1. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol. 2005;60:543–51. - PMC - PubMed
    1. Hågå A, Sverre JM. Pricing and reimbursement of pharmaceuticals in Norway. Eur J Health Econom. 2002;3:215–20. - PubMed
    1. [2007 April]. Evaluering av Trinnprismodellen (In English: Assessment of the Graded Pricing System). Norwegian Medicines Agency 2006. Available at URL: http://www.legemiddelverket.no/upload/25534/Evaluering%20av%20Trinnpriss....
    1. [2007 April]. Refusjon: Statiner—nye vilkår for refusjon (In English: Statins—New Reimbursement Regulations). Norwegian Medicines Agency 2005. Available at URL: http://www.legemiddelverket.no/templates/InterPage_21566.aspx.

MeSH terms